Area of research
Hepatology · Infectious Diseases
Research interest
Research interests include Hepatitis C virus research, HIV/AIDS drug development and treatment, Hepatitis B Virus Studies, and HIV Research and Treatment.
Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection
Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials